
Feature|Articles|August 19, 2026
From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle
Author(s)Mohd Haque
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.
Advertisement
Advertisement
Pharma companies have spent the last several years testing AI across discovery, development, manufacturing, and commercialization. With the potential to create $60 billion to $110 billion annual economic value across the industry, AI has become too important to remain stuck in pilot mode. Today, only a small group of companies is starting to turn AI into measurable business gains, with Boston Consulting Group finding that AI-first biopharma companies are reporting 5 percent to 15 percent revenue uplift.
Related to this article

With rising healthcare costs, practices are embracing flexible payment models and upfront pricing transparency to keep care accessible.

As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.

Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.

Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.

Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo CAR-T programs from Starna Therapeutics.

The future is agent-first but human when it matters — AI handles repetitive tasks while humans manage exceptions, complexity, and regulatory needs.
Advertisement
Advertisement


